Vertex reports Phase II data for VX-371 in CF

In its 3Q17 earnings report in October, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data From a Phase II trial in 142 cystic fibrosis patients ages 12 and older who are homozygous for the delta F508 CF transmembrane conductance regulator (CFTR) mutation showing that VX-371 (P-1037; GS-5737) plus hypertonic saline missed the primary endpoint of improving percent predicted forced expiratory volume in 1 second (FEV1) from baseline to day 28 vs. hypertonic saline. Specifically, VX-371 plus hypertonic saline increased ppFEV1 by 0.1% at day 28 vs. a decrease of 0.1% for hypertonic saline alone. VX-371 was generally well tolerated.

The double-blind, international trial enrolled patients who were already receiving and continued to receive Orkambi ivacaftor/lumacaftor...